FTRE1 Stock Chart & Stats
$373.00
$0.00(0.00%)
At close: 4:00 PM EDT
$373.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$373.00 - $373.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$31.63B
Enterprise Value$2.60K
Total Cash (Recent Filing)$168.60M
Total Debt (Recent Filing)$80.30M
Price to Earnings (P/E)―
Beta0.05
Next Earnings
Nov 05, 2026EPS Estimate
3.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding95,100,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.79
Price to Sales (P/S)0.58
P/FCF Ratio17.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$373.05Price Target Upside0.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)14.39
Revenue Forecast (FY)$46.02B
Bulls Say, Bears Say
Bulls Say
Improving Cash GenerationSustained positive operating cash flow and strong free cash flow provide durable internal funding for operations, deleveraging and investments. Over 2–6 months, reliable FCF reduces refinancing risk, supports liquidity cushions and enables management to pursue margin initiatives without relying on external capital.
Large Backlog And Booking MomentumA multi-billion backlog and book-to-bill above 1 indicate durable revenue visibility and improving sales execution. This pipeline converts over quarters into contracted work, smoothing top-line delivery and underpinning medium-term revenue targets and margin recovery as projects move from bid to execution.
Technology Differentiation (FIT Launch)Embedding AI-enabled FIT into clinical platforms can drive lasting efficiency gains, higher win rates and differentiated service offerings. Over months and years, platform-led productivity improvements can raise usable capacity, improve margins and strengthen competitive position in CRO services.
Bears Say
Elevated Leverage PressuresHigh leverage reduces financial flexibility and increases interest burden, constraining the company’s ability to invest in growth or absorb setbacks. Durable deleveraging will require several quarters of consistent FCF generation; until then, leverage limits strategic optionality and raises refinancing risk.
Compressed Margins And Net LossesMaterial margin compression and persistent net losses restrict retained earnings and return profiles. Even with stable revenue, lower gross and net margins make it harder to convert sales into sustainable profitability, slowing balance-sheet repair and limiting reinvestment without continued cost action.
Customer Concentration & FSP Pricing HeadwindsHeavy revenue concentration and embedded pricing concessions increase exposure to account-specific decisions and rate pressure. Structural FSP headwinds and large-client dependence make revenue and margin trajectories more volatile and complicate predictable scaling of higher-margin services.
Fortrea Holdings Inc. News
FTRE1 FAQ
What was Fortrea Holdings Inc.’s price range in the past 12 months?
Fortrea Holdings Inc. lowest stock price was $373.00 and its highest was $373.00 in the past 12 months.
What is Fortrea Holdings Inc.’s market cap?
Fortrea Holdings Inc.’s market cap is $31.63B.
When is Fortrea Holdings Inc.’s upcoming earnings report date?
Fortrea Holdings Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 94 days.
How were Fortrea Holdings Inc.’s earnings last quarter?
Fortrea Holdings Inc. released its earnings results on Jul 29, 2026. The company reported $3.991 earnings per share for the quarter, beating the consensus estimate of $3.123 by $0.868.
Is Fortrea Holdings Inc. overvalued?
According to Wall Street analysts Fortrea Holdings Inc.’s price is currently Undervalued.
Does Fortrea Holdings Inc. pay dividends?
Fortrea Holdings Inc. does not currently pay dividends.
What is Fortrea Holdings Inc.’s EPS estimate?
Fortrea Holdings Inc.’s EPS estimate is 3.77.
How many shares outstanding does Fortrea Holdings Inc. have?
Fortrea Holdings Inc. has 95,100,000 shares outstanding.
What happened to Fortrea Holdings Inc.’s price movement after its last earnings report?
Fortrea Holdings Inc. reported an EPS of $3.991 in its last earnings report, beating expectations of $3.123. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Fortrea Holdings Inc.?
Currently, no hedge funds are holding shares in MX:FTRE1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fortrea Holdings Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$373.05 (0.01% Upside)
$373.05 (0.01% Upside)
Blogger Sentiment
Bullish
MX:FTRE1 Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $105.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
218.79%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-4.24%
Trailing 12-Months
Company Description
Fortrea Holdings Inc.
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.
FTRE1 Company Deck
FTRE1 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balanced clear operational and commercial progress (book-to-bill >1.1x, adjusted EBITDA growth, large backlog, strong cost savings, FIT launch, China momentum and improved cash flow metrics) against near-term revenue pressure driven by lower pass-throughs and FSP pricing concessions, customer concentration and continued negative (though improved) Q1 cash flow. Management reiterated full-year guidance and a multi-year plan to reach mid-teens adjusted EBITDA margins. Overall, the positive operational, financial and commercial momentum and materially improved profitability and cash metrics outweigh the listed headwinds.View all MX:FTRE1 earnings summariesFTRE1 Stock 12 Month Forecast
Average Price Target
$373.05
▲(0.01% Upside)
Technical Analysis
Maravai Lifesciences Holdings
―
AbCellera Biologics
―
Recursion Pharmaceuticals
―
MBX Biosciences, Inc.
―
Generate Biomedicines, Inc.
―